After surgery patients are monitored for recurrence by monitoring Prostate Specific Antigen (PSA) levels at a follow-up clinic appointment at 6 weeks. At their clinic appointment, patients are assessed for recurrence of cancer. PSA is an enzyme produced by the prostate gland. PSA is generally checked every 3 months for the first year, then every 6 months for the next 3 years, as per guidance from the European Association of Urology [1]. Post radical surgery, a PSA of greater than 0.1 ng/mL is indicative of ‘biochemical,’ recurrence. This is interpreted to mean recurrence of cancer. As part of standard follow-up psychosexual concerns are rarely directly addressed.

Current National Institute for Clinical Excellence (NICE) guidance specifies patients should have access to erectile dysfunction services early [2]. Additionally, they also specify patients should have access to medical therapy, if they require it, or alternative treatments [2]. However, in most centres, psychosexual care is not addressed as part of current follow-up [2].